Juvaris Gets Strategic Funding
Pleasanton-based Juvaris Therapeutics, which is developing adjuvanted vaccines for improving the effectiveness of influenza vaccination, said today that it has had a second close of its Series B funding worth up to $25M. The new funding came from an undisclosed corporate investor. The firm has previously raised funding from SV Life Sciences and Kleiner Perkins Caufield & Byers. The company said the new funding will go towards advancing its platform.
posted on Wednesday, January 27, 2010 (Link to more information)
Related companies:
Juvaris Bio Therapeutics
Related stories:
> Juvaris BioTherapeutics Finds $25M
> Serus Gets Strategic Investment From Samsung
> Appirio Finds Strategic Funding
> Expect Labs Snags Strategic Investment From Intel, Samsung, and Telefonica
> GainSpan Gets Funding From In-Q-Tel
silicontap.com Home